Related Experiment Video

Updated: Aug 12, 2026

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host
09:53

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host

Published on: July 28, 2010

Effect of glucan on Leishmania major infection in BALB/c mice

A S Al Tuwaijri, A A Mahmoud, I A Al Mofleh

    Journal of Medical Microbiology
    |June 1, 1987
    PubMed

    Insights

    Glucan pretreatment significantly reduced Leishmania major parasite proliferation in BALB/c mice. This study highlights glucan

    Area of Science:

    • Immunology
    • Parasitology
    • Pharmacology

    Background:

    • Leishmania major causes cutaneous leishmaniasis.
    • BALB/c mice are a susceptible model for leishmaniasis.
    • Glucan is a polysaccharide with immunomodulatory properties.

    Purpose of the Study:

    • To investigate the therapeutic effect of glucan on Leishmania major infection in mice.
    • To evaluate glucan's impact on parasite burden and host immune response.

    Main Methods:

    • BALB/c mice were infected with Leishmania major promastigotes.
    • Glucan was administered intraperitoneally before infection.
    • Liver and spleen parasite burden was assessed at multiple time points post-infection.

    Main Results:

    • Glucan pretreatment significantly reduced Leishmania major amastigote proliferation in the liver and spleen.
    • The reduction in parasite burden was observed 4, 6, and 8 weeks post-infection.
    • A significant difference (p < 0.01) was noted in glucan-treated versus control groups.

    Conclusions:

    • Glucan demonstrates a significant protective effect against Leishmania major infection in a susceptible mouse model.
    • Glucan may be a potential therapeutic agent for leishmaniasis.
    • Further research is warranted to elucidate the mechanisms of glucan's action.

    More Related Videos

    Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs11:36

    Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs

    Published on: April 21, 2012

    In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice06:57

    In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

    Published on: February 20, 2020

    Related Concept Videos

    Leishmaniasis01:30

    Leishmaniasis

    Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
    Antiprotozoal Agents01:21

    Antiprotozoal Agents

    Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...